Accuray

US-based radiation oncology firm Accuray has received the US Food and Drug Administration (FDA) 510(k) clearance for its Radixact treatment delivery platform.

The next-generation hardware and software solutions constitute the new Radixact system and promote faster and more efficient delivery of precise treatment for a wider range of cancers.

University of Wisconsin School of Medicine and Public Health clinical associate professor Jennifer Smilowitz said: "The Radixact System builds upon the unique strengths of the TomoTherapy platform.

"Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT, an extremely accurate form of radiation therapy) to an expanded range of patients.

"New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department."

"New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department."

The Radixact system is incorporated with a powerful linear accelerator, MVCT imaging and helical treatment delivery which allow clinicians to apply highly conformal and homogenous dose distributions to any target volume while leaving the normal healthy tissue unscathed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The clinicians can tailor the delivery of their treatment in accordance to changes in tumour size, shape and location within the patient by virtue of the smart, automated workflows and midcourse decision-making tools, which feature in the new Accuray precision treatment planning system.

The Radixact System is expected to be commercially available at the end of next year.


Image: Radixact Treatment Delivery System. Photo: courtesy of PRNewsFoto / Accuray Incorporated.